China’s State Drug Administration granted approval of an inhaled COVID-19 vaccine for emergency use as a booster vaccine last week.
Vaccine manufacturer CanSino Biologics made the announcement on Sept. 4, saying it had developed and obtained approval for an inhalable COVID-19 vaccine after a proposal by China’s National Health Commission. The vaccine, called  Convidecia, uses a recombinant adenovirus that is unable to replicate.
A week prior to the announcement about the inhaled vaccine, the company reported a 98.69 percent drop in net profits for the first half of the year.
CanSino Biologics was founded in 2009 for vaccine development and production and is currently the leading manufacturer of COVID-19 vaccines in China, with a market value of nearly $5.74 billion. On Aug. 28, CanSino Biologics, announced that its revenues for the first half of 2022 was $90 million, down 69.45 percent from the same period last year, and its net profit was $1.75 million, down 98.69 percent from the same period last year….